Z-021

Ziprasidone hydrochloride solution

1 mg/mL ((as free base), Methanol:DMSO (80:20) (m/m)), certified reference material, ampule of 1 mL, Cerilliant^®

• Empirical Formula (Hill Notation): C₂₁H₂₁ClN₄OS · HCl
• CAS Number: 122883-93-6
• Molecular Weight: 449.40
• MDL number: MFCD06795476
• UNSPSC Code: 41116107

Properties

• grade: certified reference material
• Quality Level: 300
• feature: Snap-N-Spike^®/Snap-N-Shoot^®
• packaging: ampule of 1 mL
• manufacturer/tradename: Cerilliant^®
• concentration: 1 mg/mL ((as free base), Methanol:DMSO (80:20) (m/m))
• format: single component solution
• storage temp.: -10 to -25°C
• InChI: 1S/C21H21ClN4OS.ClH.H2O/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21;;/h1-4,11,13H,5-10,12H2,(H,23,27);1H;1H2
• InChI key: ZCBZSCBNOOIHFP-UHFFFAOYSA-N

Description

General description

A Certified Spiking Solution^® applicable to use in forensic drug analysis or calibrator preparation by LC/MS or GC/MS. Ziprasidone is sold under the trade names Geodon and Zeldox for treatment of schizophrenia and bipolar disorder. Recent studies have suggested that Ziprasidone may increase the risk of Type II diabetes and hyperglycemia.

Application

• Enhanced Drug Delivery Systems: A study detailed the development of sustained-release ziprasiDonemicroparticles using Soluplus and ethyl cellulose. This formulation aims to eliminate the food effect and enhance bioavailability, marking a significant advancement in pharmaceutical formulations for schizophrenia treatment (Liu W et al., 2019).


• Targeted CNS Delivery:The study evaluated the brain-targeting and antipsychotic activities of nasally administered ziprasiDonethrough lipid-polymer hybrid nanocarriers. This novel delivery method could revolutionize treatment approaches in psychiatric medicine by enhancing drug efficacy and patient compliance in schizophrenia management (Abo El-Enin HA et al., 2023).


• Real-world Effectiveness in Bipolar Disorder:The study conducted a register-based national cohort study on the real-world effectiveness of pharmacological treatments for bipolar disorder, including ziprasidone. This research provides valuable insights into the therapeutic impacts and side effect profiles of ziprasiDonein a large patient population (Lahteenvuo M et al., 2023).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Pictograms: GHS02,GHS06,GHS08
• Signal Word: Danger
• Hazard Statements: H225 - H301 + H311 + H331 - H370
• Precautionary Statements: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• Hazard Classifications: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Storage Class Code: 3 - Flammable liquids
• WGK: WGK 2
• Flash Point(F): 71.6 °F
• Flash Point(C): 22 °C